MedTrace Logo

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

NCT01435720 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-09-11

No results posted yet for this study

Summary

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

Conditions

  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Mantle Cell Lymphoma in Relapse
  • Diffuse Large B Cell Lymphoma in Relapse
  • Other B Cell Lymphoma in Relapse
  • Plasma Cell Leukemia

Interventions

BIOLOGICAL

SNS01-T

0.05 mg/kg twice weekly x 6 weeks

BIOLOGICAL

SNS01-T

0.2 mg/kg twice weekly x 6 weeks

BIOLOGICAL

SNS01-T

0.375 mg/kg twice weekly x 6 weeks

BIOLOGICAL

SNS01-T

0.0125 mg/kg twice weekly x 6 weeks

Sponsors & Collaborators

  • Senesco Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • John A Lust, MD, PhD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • United States
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435720 on ClinicalTrials.gov